TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20384426
Drug: Alcohol (0.84
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.84 g/kg for men, 0.76 g/kg for women)
Study: 15818329
Drug: Conventional immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional immunosuppressive treatment
Study: 18479175
Drug: Pantoprazole 20
Normalized name: pantoprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 20 mg/day
Study: 15225178
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg/day
Study: 28602413
Drug: Hormone Therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone Therapy and Radiation Therapy (HT-RT)
Study: 25542519
Drug: Topical artificial
Normalized name: COLOR,ARTIFICIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical artificial tears
Study: 21235700
Drug: Solifenacin (5/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin (5/10 mg)
Study: 11447543
Drug: Dilute epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dilute epinephrine irrigation (0.33 mg/L)
Study: 8056798
Drug: RD heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: RD heparin administered twice daily (50 anti-factor-Xa units/kg, subcutaneously, twice daily)
Study: 8056798
Drug: RD heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: RD heparin administered once daily (90 anti-factor-Xa units/kg, subcutaneously, once daily)
Study: 8056798
Drug: Warfarin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (5 mg orally preoperatively, adjusted daily)
Study: 3052556
Drug: Nalbuphine 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 60 mg
Study: 3052556
Drug: Nalbuphine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 30 mg
Study: 412800
Drug: Dihydrocodeine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydrocodeine 30 mg
Study: 21388622
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (CoQ) supplement (300 mg/day)
Study: 19016091
Drug: Clinician-assisted computerized
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician-assisted computerized cognitive behavioural treatment (CaCCBT)
Study: 10911512
Drug: Zaleplon 10
Normalized name: zaleplon 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zaleplon 10 mg alone
Study: 10911512
Drug: Ibuprofen 600
Normalized name: ibuprofen 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 600 mg alone
Study: 10911512
Drug: Zaleplon 10
Normalized name: zaleplon 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zaleplon 10 mg and Ibuprofen 600 mg concomitantly
Study: 10911512
Drug: Ibuprofen 600
Normalized name: ibuprofen 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 600 mg and Zaleplon 10 mg concomitantly
Study: 1598509
Drug: Ivermectin treatment
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin treatment at 6-month intervals for two years
Study: 1598509
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment at 6-month intervals for two years
Study: 6427820
Drug: Imipramine (IMI)
DrugBank: Imipramine (DB00458)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imipramine (IMI) administered orally
Study: 6427820
Drug: Imipramine (IMI)
DrugBank: Imipramine (DB00458)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imipramine (IMI) administered intramuscularly
Study: 20339879
Drug: Landiolol infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Landiolol infusion (0.125 mg/kg/min for 1 min, then 0.01‐0.04 mg/kg/min until 6 h after anesthesia)
Study: 18525385
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (usual care)
Study: 12771001
Drug: Apolipoprotein A-I/phosphatidylcholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apolipoprotein A-I/phosphatidylcholine (apoA-I/PC) disks infusion
Study: 6329395
Drug: Misonidazole administered
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misonidazole administered 4 to 5 hours before each fraction of radiotherapy (total of 11 to 13 g/m2)
Study: 6329395
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered 4 to 5 hours before each fraction of radiotherapy
Study: 17032099
Drug: Motivational enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational enhancement therapy/cognitive‐behavioral therapy (MET/CBT) plus contingency management (CM)
Study: 17032099
Drug: Motivational enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational enhancement therapy/cognitive‐behavioral therapy (MET/CBT) without CM
Study: 17032099
Drug: Individual drug
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual drug counseling (DC) plus CM
Study: 12775205
Drug: Physiotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy treatment (20 min)
Study: 11816733
Drug: Activelle (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activelle (1 mg 17 beta‐estradiol combined with 0.5 mg norethisterone acetate)
Study: 2887430
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous streptokinase (1.5 MU over one hour)
Study: 2887430
Drug: Oral aspirin
Normalized name: aspirin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral aspirin (325 mg on alternate days for 28 days)
Study: 2887430
Drug: Intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin (1000 IU h‐1 for 48 hours)
Study: 28708221
Drug: Dexamethasone (DEX)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DEX) intravitreal implant
Study: 26396166
Drug: Client-centred, activities
Approvals — FDA: no, EMA: no, PMDA: no
Description: Client-centred, activities of daily living intervention
Study: 26396166
Drug: Usual activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual activities of daily living
Study: 25919281
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (common drugs only)
Study: 22123359
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Conivaptan and Furosemide
Study: 19447264
Drug: Chiropractic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiropractic treatment at L5 using manually assisted mechanical force (Activator)
Study: 19447264
Drug: Chiropractic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiropractic treatment at L5 using traditional diversified technique spinal manipulation
Study: 19447264
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment in pain-free group
Study: 19447264
Drug: Treatment pain-free
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment pain-free group
Study: 19447264
Drug: Treatment pain
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment pain group
Study: 12165576
Drug: SLI381 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLI381 10 mg
Study: 12165576
Drug: SLI381 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLI381 20 mg
Study: 12165576
Drug: SLI381 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLI381 30 mg
Study: 9564199
Drug: Adderall 10
Normalized name: Adderall 10mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adderall 10 mg
Study: 9174180
Drug: Praziquantel (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (25 mg/kg) administered alone
Study: 9174180
Drug: Praziquantel (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (25 mg/kg) administered with cimetidine
Study: 1606596
Drug: Leuprorelin acetate
Normalized name: Leuprorelin acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leuprorelin acetate 3.75 mg every 4 weeks (n = 9)
Study: 1606596
Drug: Leuprorelin acetate
Normalized name: Leuprorelin acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leuprorelin acetate 7.5 mg every 4 weeks (n = 16)
Study: 1606596
Drug: Leuprorelin acetate
Normalized name: Leuprorelin acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leuprorelin acetate 7.5 mg monthly injections (postmenopausal study, n = 15)
Study: 1606596
Drug: Leuprorelin acetate
Normalized name: Leuprorelin acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leuprorelin acetate (both doses)
Study: 3022036
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus chest irradiation (40 Gy between cycles 1 and 2)
Study: 3022036
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus chest irradiation
Study: 24036024
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of autologous cardiosphere-derived cells (CDCs) (12.5 to 25 × 10(6))
Study: 22854401
Drug: Sucrose with
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose with whole blackcurrants (150 g served as purées) and 35 g added sucrose
Study: 22854401
Drug: Sucrose with
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose with lingonberries (150 g served as purées) and 35 g added sucrose
Study: 22854401
Drug: Sucrose with
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose with blackcurrant nectar (300 mL) and 35 g added sucrose
Study: 22854401
Drug: Sucrose with
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose with lingonberry nectar (300 mL) and 35 g added sucrose
Study: 22854401
Drug: Sucrose alone
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose alone (35 g in 300 mL water)
Study: 17145527
Drug: Intensity-modulated radiotherapy
Normalized name: California intense cedar pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity-modulated radiotherapy (IMRT) with concurrent chemotherapy (CT)
Study: 17145527
Drug: Conventional radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional radiotherapy using delayed accelerated concomitant boost radiotherapy (CBRT) with concurrent chemotherapy (CT)
Study: 14505262
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist therapy with leuprolide acetate depot (3.75 mg per month) and tibolone (2.5 mg per day) for 3-6 months
Study: 14505262
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist therapy with leuprolide acetate depot (3.75 mg per month) with add-back therapy of norethindrone acetate (5 mg per day) from the first day of treatment
Study: 11225744
Drug: Oral continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral continuous oestradiol (2.0 mg) + norethisterone acetate (1.0 mg) per day
Study: 11225744
Drug: Continuous transdermal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous transdermal oestrogen‐only (50 mg/day)
Study: 31255574
Drug: MDCK-derived H5N1
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDCK-derived H5N1 alum-adjuvanted vaccine (0.5 mL, 7.5, 15, or 30 μg of hemagglutinin)
Study: 31255574
Drug: MDCK-derived H5N1
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDCK-derived H5N1 alum-adjuvanted vaccine (30 μg HA)
Study: 31255574
Drug: MDCK-derived H5N1
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDCK-derived H5N1 alum-adjuvanted vaccine
Study: 25702876
Drug: Short-term androgen
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term androgen deprivation (4 months) with high-dose radiotherapy (76-82 Gy)
Study: 25702876
Drug: Long-term androgen
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term androgen deprivation (24 months) with high-dose radiotherapy (76-82 Gy)
Study: 23800573
Drug: Citalopram 20mg
Normalized name: Escitalopram 20mg Oral tablet
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citalopram 20mg once daily (n=38)
Study: 21557525
Drug: Rituximab 500
Normalized name: riTUXimab 500 MG in 50 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab 500 mg plus MTX
Study: 21557525
Drug: Rituximab 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab 1,000 mg plus MTX
Study: 21557525
Drug: Rituximab plus
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab plus MTX (both doses)
Study: 16741262
Drug: Arginine (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arginine (7 g)
Study: 3544622
Drug: Ketanserin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (40 mg/day)
Study: 25174679
Drug: Anthelminthic drug
Normalized name: pyrantel
DrugBank: Pyrantel (DB11156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthelminthic drug administration
Study: 18637983
Drug: Feeding assistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feeding assistance intervention (twice per day, 5 days per week for 24 weeks)
Study: 17133204
Drug: DAART (self-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAART (self-administered therapy)
Study: 10890645
Drug: Volume Assist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume Assist (VA) at 8 cm H2O/L and 12 cm H2O/L
Study: 8684741
Drug: Concentrated oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concentrated oxytocin infusion plus 10-mg PGE2 vaginal suppository every 6 hours
Study: 8684741
Drug: 20-mg PGE2
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20-mg PGE2 vaginal suppository every 4 hours
Study: 24660645
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (laser simulation)
Study: 22345050
Drug: Test mirtazapine
Normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Test mirtazapine 30 mg single-dose formulation
Study: 20412743
Drug: Cholesterol metabolism
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol metabolism modulation
Study: 20412743
Drug: Essential cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential cholesterol modulators (e.g., ATP‐binding cassette transporter A1, LDL receptor)
Study: 18052562
Drug: Gabapentin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (300 mg twice daily) for 4 weeks
Study: 16135679
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose inhaled corticosteroids (fluticasone propionate 200 mug/day) plus salmeterol
Study: 16135679
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of inhaled corticosteroids (ICS)
Study: 12431824
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with gemcitabine/cisplatin
Study: 10598596
Drug: 1.5 l
Normalized name: NUTREN 1.5 LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 l lactated Ringer's solution (LR)
Study: 10598596
Drug: 0.5 l
Normalized name: AIR 20.5 L in 100 L RESPIRATORY (INHALATION) GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 l hydroxyethylstarch solution, 6% (0.5 l HES)
Study: 10598596
Drug: 1.0 l
Normalized name: NUTREN 1.0 LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 l hydroxyethylstarch solution, 6% (1.0 l HES)
Study: 1747702
Drug: Hydroxychloroquine 400
Normalized name: hydroxychloroquine 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine 400 mg daily
Study: 25398660
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (n=29)
Study: 24226495
Drug: Unilateral spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral spinal anesthesia with 50 mg hyperbaric prilocaine 2%
Study: 24226495
Drug: Bilateral spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral spinal anesthesia with 50 mg hyperbaric prilocaine 2%
Study: 20014597
Drug: Low-dose ropivacaine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ropivacaine (0.2%)
Study: 20014597
Drug: High-dose ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ropivacaine (0.375%)
Study: 17303970
Drug: MK-0703 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0703 12.5 mg
Study: 17303970
Drug: MK-0703 50
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0703 50 mg
Study: 17303970
Drug: MK-0703 100
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0703 100 mg
Study: 11097697
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (75 mg/kg, maximum 2.5 g)
Study: 3835497
Drug: Piracetam (800‐6,400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam (800‐6,400 mg)
Study: 3835497
Drug: Piracetam-lecithin (4,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam-lecithin (4,800 mg and 25 g, respectively)
Study: 7916551
Drug: Vecuronium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.1 mg.kg‐1
Study: 31626219
Drug: Aripiprazole at
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole at a dose of up to 20 mg/day
Study: 31626219
Drug: Quetiapine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine at a dose of up to 600 mg/day
Study: 31626219
Drug: Haloperidol at
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol at a dose of up to 30 mg/day
Study: 23238778
Drug: Mosapride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride (5 mg, 3/day)
Study: 23238778
Drug: Lansoprazole (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (15 mg, 1/day)
Study: 23238778
Drug: Control (without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (without medication)
Study: 21560152
Drug: Intravesical injections
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical injections of 100 U of onabotulinumtoxinA into bladder body
Study: 21560152
Drug: Intravesical injections
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical injections of 100 U of onabotulinumtoxinA into bladder body/trigone
Study: 21560152
Drug: Intravesical injections
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical injections of 100 U of onabotulinumtoxinA into bladder base/trigone
Study: 1357450
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (calcium-channel-blocking drug plus aspirin)
Study: 4013624
Drug: Droperidol (0.014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol (0.014 mg/kg)
Study: 19489492
Drug: Chuzhen therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chuzhen therapy
Study: 20931060
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation plus oral rehydration salts (ORS)
Study: 18816596
Drug: Dexamethasone 6
Normalized name: dexamethasone 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 6 mg administered intravenously intraoperatively (Arm A)
Study: 18816596
Drug: No steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: No steroids (Arm B)
Study: 11028549
Drug: Topical antimicrobials
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antimicrobials and dressing changes
Study: 8761540
Drug: Low-calcium dialysate
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-calcium dialysate solution (LCa, 1.0 mmol/L)
Study: 8761540
Drug: Standard-calcium dialysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-calcium dialysate solution (SCa, 1.75 mmol/L)
Study: 8761540
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (CaCO3) as oral phosphate binder
Study: 1550410
Drug: Lornoxicam 6
Normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam 6 mg once daily
Study: 1550410
Drug: Lornoxicam 8
Normalized name: lornoxicam 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam 8 mg twice daily
Study: 1550410
Drug: Lornoxicam 12
Normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam 12 mg twice daily
Study: 1550410
Drug: Lornoxicam 8
Normalized name: lornoxicam 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam 8 mg daily
Study: 27070534
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight hyaluronic acid (LMW‐HA) injection (Hyalgan®, 500‐730 kDa), 3 injections
Study: 27070534
Drug: Low-energy extracorporeal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy extracorporeal shock-wave therapy (ESWT), 4 sessions
Study: 26122244
Drug: Melatonin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (0.5 mg/kg BW, max 5 mg)
Study: 23740007
Drug: Miltefosine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miltefosine (50 mg three times per day for 28 days)
Study: 18435392
Drug: One Arm
Normalized name: humanized immunoglobulin G1-kappa anti-(human B-lymphocyte antigen CD19) modified heterodimer where the heavy and light chain variable regions of one arm have been substituted by three subunits of human 4- 1BB ligand (tumor necrosis factor ligand superfa
Approvals — FDA: no, EMA: no, PMDA: no
Description: One Arm Group (both vaccines in one arm)